Ring Sulfur In The Bicyclo Ring System Patents (Class 514/301)
  • Patent number: 11678659
    Abstract: The invention relates to a use, a method and a poison in which a thrombin inhibitor, a thrombin receptor antagonist, a factor Xa inhibitor, a PAI (plasminogen activator inhibitor), a P2Y12 ADP receptor antagonist or a GPIIb/IIIa receptor antagonist are used as rodenticide.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: June 20, 2023
    Inventor: Dietrich Gulba
  • Patent number: 11578290
    Abstract: The invention relates to surfactants of general formula (I) or general formula (II) or a mixture thereof, in which R represents a linear or branched alkyl, alkenyl, alkylaryl or alkenylaryl group having 5-25 C atoms and X+ represents a charge-balancing cation. The surfactants can be incorporated into detergents or cleaning agents, have excellent technological application properties and can be produced based on renewable raw materials.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: February 14, 2023
    Assignee: Henkel AG & Co. KGaA
    Inventors: Christian Kropf, Anna Klemmer, Danuta Bedrunka, Regina Palkovits, Peter Hausoul, Carsten Stobbe
  • Patent number: 11571412
    Abstract: The present invention is directed to methods of treating AERD (aspirin exacerbated respiratory disease) and/or asthma via the administration of a thromboxane receptor antagonist to a patient in need thereof.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: February 7, 2023
    Assignee: Cumberland Pharmaceuticals Inc.
    Inventor: Leo Pavliv
  • Patent number: 11572370
    Abstract: Among other things, the present disclosure provides compounds, compositions thereof, and methods of using the same. In some embodiments, compounds of the present disclosure bind to Fc receptors, e.g., CD16a. In some embodiments, compounds of the present disclosure are useful for treating various conditions, disorders or diseases including cancer.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: February 7, 2023
    Assignee: BIOHAVEN THERAPEUTICS LTD.
    Inventors: Anna Bunin, Lawrence G. Iben, Douglas Manion, David Adam Spiegel, Matthew Ernest Welsch
  • Patent number: 11566026
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: September 15, 2020
    Date of Patent: January 31, 2023
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
  • Patent number: 11466027
    Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 11, 2022
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David
  • Patent number: 11453660
    Abstract: The present invention relates to novel dihydropyridine derivatives of formula (I): as modulators of nuclear receptors selected from androgen receptor and glucocorticoid receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of androgen receptor and/or glucocorticoid receptor, selected from cancer, metastasizing cancers, benign prostate hyperplasia, polycystic ovary syndrome (PCOS), hair loss, hirsutism, acne, hypogonadism, muscle wasting diseases, cachexia, Cushing's syndrome, anti-psychotic drug induced weight gain, obesity, post-traumatic stress disorder and alcoholism.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: September 27, 2022
    Inventors: Guido Kurz, Juan Camacho Gómez
  • Patent number: 11186572
    Abstract: The present invention relates to bacterial glutaminyl cyclases and inhibitors thereof for use in the treatment of periodontitis and related conditions, and provides a bacterial glutaminyl cyclase (bacQC); an antibody which recognizes the bacQC, a method for identifying an inhibitor of the bacQC; a compound according to Formula (I); a pharmaceutical composition comprising a bacQC inhibitor compound; a bacQC inhibitor compound and/or a pharmaceutical composition for use in a method for treatment of the human or animal body, for use in a method for therapy or prophylaxis of a bacterial infection, and for use in a method for therapy and/or prophylaxis of an acute, chronic or recurrent periodontal disease.
    Type: Grant
    Filed: December 1, 2017
    Date of Patent: November 30, 2021
    Assignee: Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung E.V.
    Inventors: Jan Potempa, Sigrun Eick, Nadine Taudte, Jens-Ulrich Rahfeld, Mirko Buchholz, Hans-Ulrich Demuth
  • Patent number: 10995111
    Abstract: The invention provides a nucleotide or nucleoside having a base attached to a detectable label via a cleavable linker, characterised in that the cleavable linker contains a moiety selected from the group comprising: Formula (I) (wherein X is selected from the group comprising O, S, NH and NQ wherein Q is a C1-10 substituted or unsubstituted alkyl group, Y is selected from the group comprising O, S, NH and N(allyl), T is hydrogen or a C1-10 substituted or unsubstituted alkyl group and * indicates where the moiety is connected to the remainder of the nucleotide or nucleoside).
    Type: Grant
    Filed: September 28, 2020
    Date of Patent: May 4, 2021
    Assignee: Illumina Cambridge Limited
    Inventors: Xiaohai Liu, John Milton, Silke Ruediger, Xiaolin Wu
  • Patent number: 10988483
    Abstract: Provided herein are compounds, pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating diseases or disorders in a subject where the subject is in need of an inhibitor of MEK where the Compound is according to Formula (I), where X, R1, R2, R2a, R3, R3a, and R3b are as described herein.
    Type: Grant
    Filed: May 18, 2018
    Date of Patent: April 27, 2021
    Assignee: NFlection Therapeutics, Inc.
    Inventors: John Kincaid, Matthew Duncton
  • Patent number: 10945999
    Abstract: The present disclosure provides a combination comprising: (i) a drug against tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II, or a pharmaceutically acceptable combination thereof. The combination may be used in the treatment and/or prevention of tuberculosis.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: March 16, 2021
    Assignees: QURETECH BIO AB, WASHINGTON UNIVERSITY IN SAINT LOUIS
    Inventors: Christina L. Stallings, Fredrik Almqvist, Kelly Flentie, James Arthur Dudley Good, Fritiof Ponten
  • Patent number: 10829496
    Abstract: Disclosed are compounds of Formula (I) or a salt or prodrug thereof, wherein: X is CR4 or N; Y is CR5 or N; provided that only one of X and Y is N; (R1) is: or; wherein R1, R1a, R1b, R1c, R2, and R3 are define herein. Also disclosed are methods of using such compounds as modulators of IRAK4, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing inflammatory and autoimmune diseases, or in the treatment of cancer.
    Type: Grant
    Filed: May 10, 2018
    Date of Patent: November 10, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Saleem Ahmad, Ling Li, Lidet A. Negash, John Hynes
  • Patent number: 10793565
    Abstract: Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: October 6, 2020
    Assignee: Incyte Corporation
    Inventors: Liangxing Wu, Bo Shen, Meizhong Xu, Wenqing Yao
  • Patent number: 10676439
    Abstract: A pyridine compound having a SF5 group on position-3 and position-4 of a pyridine ring is provided.
    Type: Grant
    Filed: November 25, 2016
    Date of Patent: June 9, 2020
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Norio Shibata, Kohei Matsuzaki, Norimichi Saito
  • Patent number: 10647725
    Abstract: 2-Aminothiophene derivatives, uses of the same, and methods of making the same, are described.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: May 12, 2020
    Assignees: The University of Toledo, Colorado State University Research Foundation
    Inventors: Steven Sucheck, Sandeep Thanna, Richard Slayden
  • Patent number: 10500205
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated to modulate the NMDA receptor.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: December 10, 2019
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Patent number: 10471048
    Abstract: The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: November 12, 2019
    Assignee: Cipla Limited
    Inventors: Karl Roberts, Geena Malhotra, Dhiraj Abhyankar, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 10398680
    Abstract: Disclosed herein are ?7?1 integrin modulatory agents and methods of using such to treat conditions associated with decreased ?7?1 integrin expression or activity, including muscular dystrophy. In one example, methods for treating a subject with muscular dystrophy are disclosed. The methods include administering an effective amount of an ?7?1 integrin modulatory agent to the subject with muscular dystrophy, wherein the ?7?1 integrin modulatory agent increases ?7?1 integrin expression or activity as compared to ?7?1 integrin expression or activity prior to treatment, thereby treating the subject with muscular dystrophy. Also disclosed are methods of enhancing muscle regeneration, repair, or maintenance in a subject and methods of enhancing ?7?1 integrin expression by use of the disclosed ?7?1 integrin modulatory agents. Methods of prospectively preventing or reducing muscle injury or damage in a subject are also disclosed.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: September 3, 2019
    Assignee: BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, RENO
    Inventors: Dean Burkin, Ryan Wuebbles
  • Patent number: 10130611
    Abstract: This application relates to a novel benzo-heterocycle derivative and more particularly, it relates a composition for preventing and treating cancer or for inhibiting metastasis comprising benzo-heterocycle derivative or pharmaceutically acceptable salts thereof as an active ingredient. The present inventors confirmed that KRS has an effect on cancer metastasis by facilitating cancer (or tumor) cell migration through interaction with 67LR, and also found that a substance inhibiting the interaction between KRS and 67LR can prevent and treat cancer by inhibiting cancer cell metastasis. Accordingly, the composition of the present invention can inhibit cancer metastasis, and thus provide a novel means for prevention and treatment of cancer.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: November 20, 2018
    Assignee: MEDICINAL BIOCONVERGENCE RESEARCH CENTER
    Inventors: Sunghoon Kim, Jin Woo Choi, Jin Young Lee, Dae Gyu Kim, Gyoon Hee Han, Jee Sun Yang, Chul Ho Lee
  • Patent number: 10105353
    Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: October 23, 2018
    Assignee: IPCA LABORATORIES LIMITED
    Inventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki Moje
  • Patent number: 10064848
    Abstract: Compounds for the preparation of pyridone derivatives are provided. In particular, compounds of formula (IA) are provided, wherein the variable groups are as defined in the specification. The compounds of formula (IA) can be used as intermediates in the preparation of pyridone derivatives useful as mitogen-activated protein kinase kinase (MEK) inhibitors and therapeutic agents for treating cancer.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 4, 2018
    Assignees: Shanghai Hengrui Pharmaceutical Co., Ltd., Jiangsu Hengrui Medicine Co., Ltd.
    Inventors: Wangyang Tu, Haitang Zhang, Guoji Xu, Jiangtao Chi
  • Patent number: 9938289
    Abstract: The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefor in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGF?-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
    Type: Grant
    Filed: January 14, 2016
    Date of Patent: April 10, 2018
    Assignee: FBM THERAPEUTICS, LLC
    Inventors: Stephen D. Barrett, James B. Kramer, Mark L. Boys, Huifen Chen
  • Patent number: 9937160
    Abstract: The present invention relates to methods of treatment of hepatitis C using prasugrel. The methods of the present invention can be used in patients with hepatitis C administering prasugrel in combination with one or more anti-hepatitis C drugs.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: April 10, 2018
    Assignee: Cipla (UK) Limited
    Inventors: Karl Roberts, Geena Malhotra, Dhiraj Abhyankar, Kalpana Joshi, Jeevan Ghosalkar
  • Patent number: 9913831
    Abstract: Disclosed is a treatment of diabetes insipidus. Methods of treating diabetes insipidus disorders associated with P2Y receptors using the compounds and compositions are also disclosed.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: March 13, 2018
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Bellamkonda K. Kishore, Noel G. Carlson, Yue Zhang
  • Patent number: 9815848
    Abstract: This invention provides a new preparation method of Clopidogrel Hydrogen Sulfate spherical crystal form I, using single 2-butanol as solvent, controlling the concentration, addition way and addition speed of sulfuric acid used to salify to shorten the process time, thus separating out Clopidogrel Hydrogen Sulfate from solution system stably with spherality. And the Clopidogrel Hydrogen Sulfate obtained complies with the requirements of the follow-up process on residual solvent, bulk density and mobility.
    Type: Grant
    Filed: December 31, 2014
    Date of Patent: November 14, 2017
    Assignees: TIANJIN UNIVERSITY, SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD
    Inventors: Junbo Gong, Qi Wang, Qiuxiang Yin, Jingkang Wang, Xiaopeng Song, Baohong Hou, Liting Liao, Duanming Tan, Ziyuan Di
  • Patent number: 9778248
    Abstract: With a method for measurement of thrombocyte function, a solution is created, by which the sensitivity of individual thrombocytes can be measured with the least possible apparatus effort, with high throughput, by passing a liquid thrombocyte solution, in which the thrombocytes are present in isolated form, into a microfluidic chamber and brought into contact with at least one stimulant, wherein an electrical field directed transverse to the entry direction of the thrombocyte solution is applied to the chamber, and the movement path of the thrombocytes in the electrical field is observed and evaluated, in such a manner that thrombocytes having a movement path directed in the direction toward the minus pole of the electrical field are classified as non-activated thrombocytes, and thrombocytes having a movement path directed in the direction toward the plus pole of the electrical field are classified as activated thrombocytes.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: October 3, 2017
    Assignee: Leibniz—Institut fuer Analytische Wissenschaften—ISAS—e.V.
    Inventors: Jonathan West, Dirk Janasek, Albert Sickmann
  • Patent number: 9657014
    Abstract: The present invention relates to the use of compounds of general formula I wherein R?, R1, R2 and R3 are as defined herein, or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, and for methods to treat a variety of neurodegenerative and neuropsychiatric diseases.
    Type: Grant
    Filed: May 20, 2015
    Date of Patent: May 23, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Simona M. Ceccarelli, Ravi Jagasia, Roland Jakob-Roetne, Rainer E. Martin, Jens-Uwe Peters, Juergen Wichmann
  • Patent number: 9562015
    Abstract: The present invention comprises compounds and compositions thereof for enhanced drug delivery. Pro-drug and double pro-drug derivatives of corticosteroids non-steroid anti-inflammatory drugs (NSAIDs), and ruboxistaurin for delivery to the eye are provided. The compounds and compositions are useful for treating various ocular diseases, including ocular diseases effecting the posterior segments of the eye. In addition, the present invention is directed to particle in particle carrier formulations for sustained release of therapeutic agents.
    Type: Grant
    Filed: November 16, 2012
    Date of Patent: February 7, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY
    Inventors: Uday B. Kompella, Ashish Thakur
  • Patent number: 9539246
    Abstract: Disclosed is a treatment of diabetes insipidus. Methods of treating diabetes insipidus disorders associated with P2Y receptors using the compounds and compositions are also disclosed.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: January 10, 2017
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Bellamkonda K. Kishore, Noel G. Carlson, Yue Zhang
  • Patent number: 9512118
    Abstract: The present invention relates to a crystal of 1-ethyl-7-methyl-3-{4-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)oxy]phenyl}-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one useful as a prophylactic or therapeutic agent for schizophrenia and the like, which shows an X-ray powder diffraction pattern having characteristic peaks at interplaner spacings (d) of 13.59 plus or minus 0.2 and 6.76 plus or minus 0.2 Angstroms in powder X-ray diffraction.
    Type: Grant
    Filed: June 21, 2012
    Date of Patent: December 6, 2016
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventor: Katsuhiko Yamamoto
  • Patent number: 9504678
    Abstract: The present disclosure provides oral dosage forms comprising an antiplatelet agent and an acid inhibitor, as well as methods of treating subjects with an antiplatelet agent and an acid inhibitor.
    Type: Grant
    Filed: April 4, 2007
    Date of Patent: November 29, 2016
    Assignee: KG ACQUISITION LLC
    Inventors: Mark A. Goldsmith, Elizabeth Vadas
  • Patent number: 9480680
    Abstract: The present disclosure provides ready-to-use, oil/water emulsion compositions with mean droplet size (intensity-average, m) of 100-500 nm, wherein the oil phase comprises clopidogrel free base dispersed in pharmaceutical acceptable oil(s). The emulsion uses clopidogrel free base or premix of clopidogrel free base in oil(s) as the starting materials and may also contain one or more excipients such as surfactant and or co-surfactant, osmotic agent, pH adjustment agent, antioxidant, preservative, sweetener, and/or suspending agent, etc. The emulsion formulations and method of manufacturing significantly improves the stability of clopidogrel over other aqueous based formulations (such as cyclodextrin-based formulations and emulsion made using clopidogrel salt as the starting materials) with respect to chiral degradation, hydrolytic, and thermal degradation.
    Type: Grant
    Filed: February 6, 2014
    Date of Patent: November 1, 2016
    Inventor: Jingjun Huang
  • Patent number: 9402907
    Abstract: An object of the present invention is to provide a pharmaceutical composition containing compound I or a pharmacologically acceptable salt thereof, or a solvate thereof as an active ingredient, which is favorably dissolved in the neutral region. The present invention relates to a pharmaceutical composition containing (A) N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino}cyclohexyl)ethanediamide or a pharmacologically acceptable salt thereof, or a solvate thereof, and (B) an acid or a salt thereof.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: August 2, 2016
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Koichi Ishidoh, Kazuhiro Matsuura
  • Patent number: 9403842
    Abstract: The present invention relates to prasugrel or a pharmaceutically compatible salt thereof, compositions that contain this active substance and pharmaceutical compositions that contain this active substance or a composition containing this active substance. The present invention further relates to methods for producing the novel compositions.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: August 2, 2016
    Assignee: ratiopharm GmbH
    Inventors: Sandra Brueck, Jana Paetz
  • Patent number: 9271972
    Abstract: The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-?B activation to treat viral infections and inflammatory conditions.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: March 1, 2016
    Assignee: University of Massachusetts
    Inventors: Robert W. Finberg, Evelyn A. Kurt-Jones, Shenghua Zhou
  • Patent number: 9248122
    Abstract: The invention relates to substituted heteroquinoline-3-carboxamides, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: February 2, 2016
    Assignee: GRÜNENTHAL GMBH
    Inventors: Sven Kühnert, Simon Lucas, Gregor Bahrenberg, Wolfgang Schröder
  • Patent number: 9193713
    Abstract: The present invention relates compounds of formula (I) wherein A and R1 are as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: November 24, 2015
    Assignee: AbbVie Inc.
    Inventors: William A. Carroll, Michael J. Dart, Arturo Perez-Medrano, Derek W. Nelson, Tongmei Li, Sridhar Peddi, Jennifer Frost, Teodozyj Kolasa, Bo Liu, Steven P. Latshaw, Xueqing Wang
  • Patent number: 9170126
    Abstract: An electronic device is described that includes a range indicator for conveying a range of travel until the electronic device ceases operation due to loss of power. In implementations, the electronic device includes a display device, a memory operable to store one or more modules, and at least one processor coupled to the display device and the memory. The processor is operable to execute the one or more modules to cause display of navigation information at the display device. The navigation information includes a map graphic representing an area an aircraft is traversing. The navigation information also includes an end of use situation that represents a range of travel for the aircraft until the electronic device ceases operation due to a loss of power.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: October 27, 2015
    Assignee: Garmin International, Inc.
    Inventors: Christopher E. P. Schulte, Douglas E. Leeper, Jr.
  • Patent number: 9138392
    Abstract: Provided is a nontherapeutic cosmetic process for depigmenting, lightening and/or whitening keratin materials applying an effective amount of at least one compound of formula (I): or a tautomer thereof of formula (I?): to a keratin material, where the structural variables are as defined herein.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: September 22, 2015
    Assignee: L'OREAL
    Inventor: Xavier Marat
  • Patent number: 9133186
    Abstract: Disclosed is a compound which is useful as an AMPK activator. A compound represented by the formula: its pharmaceutically acceptable salt, or a solvate thereof, wherein a group represented by the formula: is a group represented by the formula: R1 is each independently halogen, hydroxy, cyano, nitro, carboxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl or the like; m is an integer of 0 to 3; R2 is hydrogen, or substituted or unsubstituted alkyl; X is —O—; and Y is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.
    Type: Grant
    Filed: September 8, 2011
    Date of Patent: September 15, 2015
    Assignee: Shionogi & Co., Ltd.
    Inventors: Keisuke Tonogaki, Akira Ino, Eiichi Kojima, Manabu Katou, Masafumi Iwatsu, Nobuyuki Tanaka, Masahiko Fujioka
  • Publication number: 20150148308
    Abstract: A harmful arthropod control composition comprising a compound represented by the following Formula (1) wherein each symbol represents definitions described in the specification, and one or more fungicidal compounds, which are selected from among azoles, strobilurins, phenylamides, rice blast controlling compounds, rice sheath blight disease controlling compounds, and other fungicidal compounds. The composition has an excellent controlling effect against harmful arthropods.
    Type: Application
    Filed: June 5, 2013
    Publication date: May 28, 2015
    Applicant: Sumitomo Chemical Company, Limited
    Inventors: Tatsuya Suzuki, Atsushi Iwata, Yoshihiko Nokura
  • Patent number: 9040707
    Abstract: The present invention relates to novel bicyclic thiazoles which are positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (“mGluR5”) and which are useful for the treatment or prevention of disorders associated with glutamate dysfunction and diseases in which the mGluR5 subtype of receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which mGluR5 is involved.
    Type: Grant
    Filed: December 16, 2010
    Date of Patent: May 26, 2015
    Assignee: Janssen Pharmaceutica NV
    Inventors: Gregor James MacDonald, Andrés Avelino Trabanco-Suárez, Susana Conde-Ceide, Gary John Tresadern, José Manuel Bartolomé-Nebreda, Joaquin Pastor-Fernández
  • Publication number: 20150141423
    Abstract: Disclosed are pesticidally active pyridyl- and pyrimidyl-substituted thiazole derivatives, processes for their preparation, compositions comprising those compounds, and their use for controlling insects.
    Type: Application
    Filed: June 4, 2013
    Publication date: May 21, 2015
    Applicant: Syngenta Participations AG
    Inventors: Ruifang Chen, Laura Quaranta, Andrew Edmunds, Andre Jeanguenat, Aurelien Bigot, Sebastian Rendler, Roger Graham Hall, Long Lu, Peter Renold
  • Patent number: 9034896
    Abstract: The present invention relates to novel N-(imidazolidin-2-ylidene) Heterocyclopenta[b]pyridine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.
    Type: Grant
    Filed: April 21, 2014
    Date of Patent: May 19, 2015
    Assignee: Allergan, Inc.
    Inventors: Santosh C. Sinha, Liming Wang, Ken Chow, Mohammed I. Dibas, Michael E. Garst
  • Patent number: 9029378
    Abstract: Substituted bicyclic aromatic carboxamide and urea compounds as vanilloid receptor ligands, pharmaceutical compositions containing these compounds, and a method of using these compounds in the treatment and/or inhibition of pain and further diseases and/or disorders mediated at least in part via the vanilloid receptor 1 (VR1/TRPV1).
    Type: Grant
    Filed: July 25, 2012
    Date of Patent: May 12, 2015
    Assignee: Gruenenthal GmbH
    Inventors: Robert Frank, Thomas Christoph, Bernhard Lesch, Jeewoo Lee
  • Patent number: 9029390
    Abstract: The invention relates to non hemolytic compositions containing an antiplatelet agent such as clopidogrel or ticlopidine; these compositions being characterized in that the antiplatelet agent is in the form of free base, and the composition contains at least one hydrophilic non ionic surfactant. The invention relates also a galenic form, a method of preparation of thereof, as well as therapeutic uses of thereof, especially in patients who suffer from undesirable effects related to hemolysis and/or gastrointestinal acidity.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: May 12, 2015
    Assignee: CLL Pharma
    Inventors: Thierry Breul, Claude Laruelle
  • Publication number: 20150126529
    Abstract: Disclosed are azaindazole compounds of Formula (I): or a pharmaceutically acceptable salt thereof, wherein: X is O and Y is N; or X is S and Y is CH; Z is CR2 or N; Q is a heteroaryl; and R1 is defined herein. Also disclosed are methods of using such compounds in the treatment of at least one CYP17 associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: January 16, 2015
    Publication date: May 7, 2015
    Inventors: Upender Velaparthi, Peiying Liu
  • Publication number: 20150126545
    Abstract: A composition comprises a kinase inhibitory compound, e.g., N-(4-{4-amino-7-[1-(2-hydroxyethyl)-1H-pyrazol-4-yl]thieno[3,2-c]pyridin-3-yl}phenyl)-N?-(3-fluorophenyl)urea, in a mixture comprising (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. The composition is suitable for dilution with an IV solution for administration to a subject in need thereof for treatment of a cancer.
    Type: Application
    Filed: December 14, 2012
    Publication date: May 7, 2015
    Applicant: AbbVie Inc.
    Inventors: Yi Shi, Josh M. Lipari, Brian E. Padden, Lloyd S. Dias, Julie K. Spence
  • Patent number: 9018207
    Abstract: The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects. The AT2 receptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of neuropathic conditions.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: April 28, 2015
    Assignee: Spinifex Pharmaceuticals Pty Ltd
    Inventors: Maree Therese Smith, Bruce Douglas Wyse
  • Patent number: 9012641
    Abstract: Salts of prasugrel were prepared including, for example, crystalline forms of prasugrel hydro bromide. These salts are useful, for example, in medicaments that inhibit the aggregation of platelets.
    Type: Grant
    Filed: July 22, 2014
    Date of Patent: April 21, 2015
    Assignee: Teva Pharmaceuticals Industries Ltd.
    Inventors: Mihaela Tuksar, Tomislav Biljan, Miroslav Zegarac